Intrance Medical Systems

Intrance Medical Systems, Inc., a subsidiary of Swedish Intrance Holdings AB, is a private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson's disease in the United States, Canada, South America, Japan, and Taiwan, China. Intrance’s lead product, known as Lecigon™ in the Nordic countries and certain European markets, is a fixed-dose combination therapy of levodopa, carbidopa, and entacapone for enteral infusion in patients with advanced Parkinson's disease. The company is planning to advance its U.S. clinical development program in this target indication and has recently submitted a new drug research (IND) application to the U.S. Food and Drug Administration (FDA).